Pharmaceuticals

Anti-Asthmatics And COPD Drugs Market Outlook 2026–2035: Growth Drivers and Industry Forecast

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the anti-asthmatics and copd drugs market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Anti-Asthmatics And COPD Drugs Market size between 2026 and 2035?

The market for anti-asthmatics and COPD drugs has experienced consistent expansion over recent years. This market is projected to expand from $85.08 billion in 2025 to $89.13 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.8%. Historically, this expansion has been driven by factors such as the increasing occurrence of asthma and COPD, elevated levels of smoking and air pollution, restricted knowledge regarding preventive treatments, the widespread availability of generic bronchodilators, and the expansion of hospital pharmacy networks.

The anti-asthmatics and COPD drugs market is anticipated to show significant expansion in the coming years. It is projected to grow to $111.34 billion by 2030, at a compound annual growth rate (CAGR) of 5.7%. This expected growth over the forecast period is driven by advancements in biologics and monoclonal antibodies, the incorporation of AI into treatment regimens, the increasing adoption of digital health solutions, the broadening of online pharmacy channels, and the development of targeted therapies for severe COPD. Noteworthy trends during this period include personalized asthma management, the use of telemedicine and remote patient monitoring, the progress in creating inhalable biologics, a growing inclination towards combination therapies, and a focus on formulations for pediatric and geriatric patients.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3802&type=smp

Which Drivers Are Impacting Market Performance In The Anti-Asthmatics And COPD Drugs Market?

The widespread occurrence of asthmatic conditions is projected to stimulate growth in the anti-asthmatics and COPD drugs market moving forward. Asthma is characterized as a long-term ailment causing inflammation and swelling in the airways, which leads to a narrowing of the passages carrying air from the nose and mouth to the lungs. Due to an increase in asthma cases, there has been a significant rise in identifying new anti-asthmatics and COPD drugs for treating these disorders. For instance, in June 2025, according to the Official Statistics, a UK-based government department, the rate of emergency admissions for asthma in adults (19+) saw a 17% increase in the financial year ending 2024, compared to the previous year. Thus, the escalating number of asthmatic disorders drives the development of novel drugs, which will further propel the asthma drug market.

Which Segments Are Contributing To The Growth Of The Anti-Asthmatics And COPD Drugs Market?

The anti-asthmatics and copd drugs market covered in this report is segmented –

1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs

2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers

3) By End User: Asthma Patients, COPD Patients

4) By Therapy: Preventive, Curative

5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous

6) By Age Group: Below 5, 5-14, 15-60, Above 60

Subsegments:

1) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics (Short-Acting And Long-Acting), Methylxanthines

2) By Anti-Inflammatory Drugs: Corticosteroids (Inhaled And Systemic), Leukotriene Modifiers, Phosphodiesterase-4 Inhibitors

3) By Monoclonal Antibodies: Anti-IgE Antibodies, Anti-IL-5 Antibodies, Anti-IL-4 Or IL-13 Antibodies

4) By Combination Drugs: Combination Bronchodilator Inhalers (LABA + LAMA), Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)

How Are Emerging Trends Affecting The Progression Of The Anti-Asthmatics And COPD Drugs Market?

Leading companies active in the anti-asthmatics and COPD drugs market are prioritizing technological advancements, such as next-generation propellant inhalers, to address the growing need for environmentally sustainable and patient-friendly respiratory treatments. Next-generation propellant technology substitutes traditional hydrofluoroalkane (HFA) propellants with alternatives that have a near-zero Global Warming Potential (GWP), thereby reducing the carbon footprint of pressurized metered-dose inhalers (pMDIs) while preserving drug delivery efficiency. For example, in May 2025, AstraZeneca plc, a UK-based biopharmaceutical company, introduced Trixeo Aerosphere, an innovative fixed-dose triple-combination therapy for COPD incorporating budesonide, glycopyrronium, and formoterol fumarate, now delivered via a next-generation propellant. This pMDI ensures bioequivalence to previous formulations, retains its established safety and efficacy profile, and offers a 99.9% reduction in GWP compared to traditional propellants. Trixeo Aerosphere supports sustainable healthcare practices without compromising clinical outcomes, presenting an effective, low-carbon-footprint option for patients requiring inhaled respiratory therapy.

Who Are The Top-Performing Companies In The Anti-Asthmatics And COPD Drugs Market In Recent Years?

Major companies operating in the anti-asthmatics and copd drugs market are GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, Lupin Limited, Abbott Laboratories, Pfizer, Vectura Group, Bayer, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Aspen Nigeria.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

Which Region Currently Holds The Largest Share Of The Anti-Asthmatics And COPD Drugs Market?

North America was the largest region in the anti-asthmatics and COPD drugs market in 2025. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and COPD drugs market during the forecast period. The regions covered in the anti-asthmatics and copd drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Anti-Asthmatics And COPD Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3802&type=smp

Browse Through More Reports Similar to the Global Anti-Asthmatics And COPD Drugs Market 2026, By The Business Research Company

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Asthma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795